1. Home
  2. USARW vs JAGX Comparison

USARW vs JAGX Comparison

Compare USARW & JAGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • USARW
  • JAGX
  • Stock Information
  • Founded
  • USARW N/A
  • JAGX 2013
  • Country
  • USARW United States
  • JAGX United States
  • Employees
  • USARW N/A
  • JAGX 49
  • Industry
  • USARW Metal Mining
  • JAGX Biotechnology: Pharmaceutical Preparations
  • Sector
  • USARW Basic Materials
  • JAGX Health Care
  • Exchange
  • USARW Nasdaq
  • JAGX Nasdaq
  • Market Cap
  • USARW N/A
  • JAGX 3.1M
  • IPO Year
  • USARW 2023
  • JAGX N/A
  • Fundamental
  • Price
  • USARW $0.68
  • JAGX $4.85
  • Analyst Decision
  • USARW
  • JAGX
  • Analyst Count
  • USARW 0
  • JAGX 0
  • Target Price
  • USARW N/A
  • JAGX N/A
  • AVG Volume (30 Days)
  • USARW N/A
  • JAGX 37.8K
  • Earning Date
  • USARW N/A
  • JAGX 03-31-2025
  • Dividend Yield
  • USARW N/A
  • JAGX N/A
  • EPS Growth
  • USARW N/A
  • JAGX N/A
  • EPS
  • USARW N/A
  • JAGX N/A
  • Revenue
  • USARW N/A
  • JAGX $11,689,000.00
  • Revenue This Year
  • USARW N/A
  • JAGX $18.18
  • Revenue Next Year
  • USARW N/A
  • JAGX $40.06
  • P/E Ratio
  • USARW N/A
  • JAGX N/A
  • Revenue Growth
  • USARW N/A
  • JAGX 19.75
  • 52 Week Low
  • USARW N/A
  • JAGX $4.41
  • 52 Week High
  • USARW N/A
  • JAGX $540.00
  • Technical
  • Relative Strength Index (RSI)
  • USARW N/A
  • JAGX 20.48
  • Support Level
  • USARW N/A
  • JAGX $4.41
  • Resistance Level
  • USARW N/A
  • JAGX $5.45
  • Average True Range (ATR)
  • USARW 0.00
  • JAGX 0.95
  • MACD
  • USARW 0.00
  • JAGX 0.00
  • Stochastic Oscillator
  • USARW 0.00
  • JAGX 3.54

About JAGX Jaguar Health Inc.

Jaguar Health Inc is a commercial-stage pharmaceuticals company focused on developing novel, plant-based, non-opioid, and sustainably derived prescription medicines for people and animals with GI distress, specifically chronic, debilitating diarrhea. Its product Mytesi is a novel, first-in-class anti-secretory agent which has a basic normalizing effect locally on the gut, and this mechanism of action has the potential to benefit multiple disorders. It has two reportable segments namely human health and animal health. The company generates the majority of its revenue from the Human Health segment.

Share on Social Networks: